FIG 4.

Efficacy of therapeutic anti-VEEV TcPAb treatment against standard-dose aerosol challenge. Six-week-old BALB/c mice were treated once i.p. or i.p./i.n. with 100 μg of either the control TcPAb or the indicated anti-VEEV TcPAb 12 h after aerosol challenge with a standard-dose aerosol (50 to 100 LD₅₀) of V3000 nluc TaV. (H) Four mice from the control or therapeutic groups were imaged by IVIS analysis at 5 days postchallenge, and photon flux was quantitated for the head. (A to G) One mouse representing the fewest clinical infection signs and one mouse representing the greatest number and severity of clinical infection signs are shown in IVIS images from the control (A) or therapeutic (B to G) groups. All IVIS images are set to the same scale. Daily weights are shown for mice that received the negative-control TcPAb (black lines) (B to G) or therapeutic (colored lines) (B to G) treatments. (H) None of the treatments were significantly different from the control by Student's t test (P > 0.05).